Summary:
In adults with type 2 diabetes (T2D), mycoprotein and guar gum significantly reduced postprandial glucose (PG) compared to a control group, though it was associated with minimal and clinically insignificant gastrointestinal side effects.
Source: Anna Cherta-Murillo, et al. “Investigating the effects of mycoprotein and guar gum on postprandial glucose in type 2 diabetes: a double-blind randomised controlled trial.” Read article here.
| PICO | Description |
|---|---|
| Population | Adults with type 2 diabetes from white European and South Asian ethnic groups. |
| Intervention | Mycoprotein and guar gum supplementation during meals. |
| Comparison | A control group receiving meals without mycoprotein and guar gum supplementation. |
| Outcome | Significant reductions in postprandial glucose levels were observed in the mycoprotein and guar gum group compared to controls. The intervention yielded similar benefits independent of ethnicity and was associated with minimal gastrointestinal side effects. |
RCT
Nutr Diabetes · 2025
Mycoprotein and guar gum on postprandial glucose in T2D
Crossover RCT · type 2 diabetes · acute
Trial design
Between-group effect (95% CI)
Guar gum vs none
-197.4
PG iAUC, p<0.001
Mycoprotein vs chicken
-129.8
PG iAUC, p=0.002
Both effects
Significant
95% CI excludes 0
Appetite outcomes
No effect
GLP-1, PYY, intake
⬡ Bottom Line
In adults with type 2 diabetes, both mycoprotein (vs chicken) and guar gum (vs none) independently and significantly lowered the postprandial glucose response, with benefits seen in white European and south Asian participants and no meaningful effect on appetite.
P
Population
Adults with type 2 diabetes (white European and south Asian)
I
Intervention
Mycoprotein and guar gum taken with meals
C
Comparator
Matched meals without mycoprotein or guar gum (soy/chicken)
O
Outcome
Postprandial glucose iAUC (with insulin, GLP-1, PYY, appetite)
